Skip to content
Screener

Sarepta Therapeutics, Inc. SRPT Q1 2025 earnings

Reported May 6, 2025 · After market close

Revenue$744.9MBeat by $5.3M
EPS-$3.42Miss by $3.77
Revenue estimate$739.6M
EPS estimate$0.35

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$354.7M
EPS estimate$0.17

Financials

Q1 2025

Income statement

See full
Revenue$744.9M+80.2%
Operating income-$300.4M-961%
Net income-$447.5M-1,339%
EPS (diluted)-$4.60-1,343%

Balance sheet

See full
Cash & equivalents$240.9M-43.6%
Total debt$205.5M-16.4%
Total equity$1.2B+23.8%
Total assets$3.5B+7.5%

Cash flow

See full
Operating cash flow-$583.4M-141%
CapEx$43.7M+34.5%
Free cash flow-$627.1M-128%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$6.19B-49.1%
Enterprise value$6.16B-48.6%

Returns & leverage

See full
Return on equity-23.1%-28.0pp
Debt / equity0.2×-0.1×
Current ratio4×0.0×

Segments

By product

See full
Elevidys$375.0M—
Pmo Products$236.5M—

By segment

See full
All Other Segments$744.9M+80.2%

FAQ

When did Sarepta Therapeutics, Inc. report Q1 2025 earnings?
Sarepta Therapeutics, Inc. (SRPT) reported Q1 2025 earnings on May 6, 2025 after market close.
What were Sarepta Therapeutics, Inc.'s Q1 2025 revenue and EPS?
Sarepta Therapeutics, Inc. reported revenue of $744.9M and eps of $-3.42 for Q1 2025.
Did Sarepta Therapeutics, Inc. beat estimates in Q1 2025?
Revenue beat the consensus estimate of $739.6M by $5.3M. EPS missed the consensus estimate of $0.35 by $3.77.
How did Sarepta Therapeutics, Inc.'s Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 80.2% from $413.5M a year earlier.
Where can I find Sarepta Therapeutics, Inc.'s Q1 2025 SEC filings?
You can read the 10-Q periodic report (0000950170-25-064412) directly on SEC EDGAR. The filing index links above go to sec.gov.